Haemostasis Journal Club September 2025

Keep informed about evolving science and clinical practice with our compilation of the latest studies, guidelines, and perspectives in haemostasis.

GUIDELINES

• Barrett WJ, Kaucher KA, Orpet RE, et al. Tranexamic acid in trauma: A joint position statement and resource document of NAEMSP, ACEP, and ACS-COT. J Trauma Acute Care Surg. 2025;99(3):357-363. doi:10.1097/TA.0000000000004727
• Lier H, Goossen K, Kugler CM, et al. Inhospital coagulation management and fluid replacement therapy in patients with multiple and/or severe injuries – a systematic review and clinical practice guideline update. Eur J Trauma Emerg Surg. 2025;51(1):240.  doi:10.1007/s00068-025-02919-2
• Sandner S, Gaudino M, Agewall S, et al. Antithrombotic therapy after coronary artery bypass graft surgery: a Clinical Consensus Statement of the ESC Working Group on Cardiovascular Surgery, the ESC Working Group on Cardiovascular Pharmacotherapy, and the European Association for Cardio-Thoracic Surgery (EACTS). Eur J Cardiothorac Surg. 2025;67(8):ezaf243. doi:10.1093/ejcts/ezaf243

PERSPECTIVES & REVIEWS

• Fellah LC, M Silva L. Plasminogen Activation in Oral Mucosal Immunopathology. Arterioscler Thromb Vasc Biol. 2025;45(9):1479-1487. doi:10.1161/ATVBAHA.125.322733
• Fletcher-Sandersjöö A, Sebghati J, Thelin EP. Hemostatic disturbances in traumatic brain injury: from mechanism to management. Acta Neurochir (Wien). 2025;167(1):146. doi:10.1007/s00701-025-06549-w
• Luyendyk JP, Flick MJ, Wolberg AS. Factor XIII: driving (cross-)links in hemostasis, thrombosis, and disease. Blood. 2025;146(12):1412-1421. doi:10.1182/blood.2024025321
• Molina JJ, Flores-Mireles AL. Role of Clot Formation and Plasminogen Activation in Lower Urinary Tract Pathologies. Arterioscler Thromb Vasc Biol. 2025;45(9):1471-1478. doi:10.1161/ATVBAHA.125.321600
• Pishko AM, Li A, Cuker A. Immune Thrombotic Thrombocytopenic Purpura: A Review. JAMA. 2025;334(6):517–529. doi:10.1001/jama.2025.3807
• Swieringa F, Heemskerk JWM, Assinger A. Platelet activation and signaling in thrombus formation. Blood. 2025;146(12):1400-1411. doi:10.1182/blood.2024025320
• Tucker LJ, Hilmas K, Brown AC. Structure-based design of therapeutics to control hemostasis. Blood. 2025;146(12):1431-1439. doi:10.1182/blood.2024025323
• Weisel JW, Litvinov RI. Exploring the thrombus niche: lessons learned and potential therapeutic opportunities. Blood. 2025;146(12):1389-1399. doi:10.1182/blood.2024025319

CLINICAL TRIALS 

• Alexander JH, Lydon EJ, Piccini JP, et al. Asundexian or Apixaban in Patients With Atrial Fibrillation According to Prior Oral Anticoagulant Use: A Subgroup Analysis of the OCEANIC-AF Randomized Clinical Trial. JAMA Cardiol. 2025;10(6):555-563. doi:10.1001/jamacardio.2025.0277
• Barbosa LM, Oliveira VMR, Araujo B, et al. Reduced dose versus full dose of direct oral anticoagulation in extended treatment of venous thromboembolism: an updated meta-analysis of randomized controlled trials. J Thromb Haemost. 2025:S1538-7836(25)00492-1 doi:10.1016/j.jtha.2025.07.029
• Burša F, Frelich M, Sklienka P, et al. Activated Partial Thromboplastin Time and Anti-IIa Monitoring in Argatroban Anticoagulation in COVID-19 Patients on Venovenous Extracorporeal Membrane Oxygenation. Clin Appl Thromb Hemost. 2025;31:10760296251341315. doi:10.1177/10760296251341315
• Dehbi HM, Fischer U, Åsberg S, et al. Collaboration on the optimal timing of anticoagulation after ischaemic stroke and atrial fibrillation: a systematic review and prospective individual participant data meta-analysis of randomised controlled trials (CATALYST). Lancet. 2025;406(10498):43-51. doi:10.1016/S0140-6736(25)00439-8
• Gorter KAM, Stehouwer MC, de Vroege R, et al. Comparison of Two Activated Clotting Time Targets During Cardiac Surgery With Cardiopulmonary Bypass: A Prospective Multicenter Randomized Controlled Trial. J Cardiothorac Vasc Anesth. 2025;8:S1053-0770(25)00558-0. doi:10.1053/j.jvca.2025.07.001
• Lefebvre M, Cachanado M, Chatellier G, et al. Effects on mortality of extended versus short-term anticoagulation in venous thromboembolism: a systematic review and meta-analysis of randomized trials. Res Pract Thromb Haemost. 2025;9(4):102928. doi:10.1016/j.rpth.2025.102928
• Kim JY, Hwang T, Park SK, et al. Real-world safety and effectiveness of rurioctocog alfa pegol in 338 patients with hemophilia A in South Korea: A postmarketing surveillance study. Thromb Res. 2025;253:109402. doi:10.1016/j.thromres.2025.109402
• Rahe-Meyer N, Roy A, Trouillier HH, et al. Efficacy and safety of human fibrinogen concentrate (BT524) in patients with major haemorrhage undergoing major orthopaedic or abdominal surgery (AdFIrst): a randomised, active-controlled, multicentre, partially blinded, phase 3 non-inferiority trial. EClinicalMedicine. 2025;85:103264. doi:10.1016/j.eclinm.2025.103264
• Young G, Mahlangu J, Boggio LN, et al. Treatment of severe bleeds with eptacog beta in hemophilia A or B with inhibitors: a post hoc analysis of the PERSEPT 1 and 2 trials. Blood Vessel Thromb Hemost. 2025;2(3):100069. doi:10.1016/j.bvth.2025.100069

CASE SERIES & RETROSPECTIVE STUDIES

• Almatar E, Alsharidah S, Hashem OA. Outcomes of recombinant activated factor VIIa (NovoSeven) therapy in glanzmann thrombasthenia: two case reports. Blood Coagul Fibrinolysis. 2025;36(6):293-295. doi:10.1097/MBC.0000000000001380
• Al Tannir AH, Biesboer EA, Tentis M, et al. Evaluating the efficacy and safety of low-molecular weight heparin as a chemoprophylactic agent in stable traumatic brain injury. Am J Surg. 2025;246:116389. doi:10.1016/j.amjsurg.2025.116389
• Bea S, Iyer GS, Kim DH, et al. Oral anticoagulation and risk of adverse clinical outcomes in venous thromboembolism. JAMA Intern Med. 2025;185(7):837-846. doi:10.1001/jamainternmed.2025.1109
• Cappelletti D, Bianco F, Bucciarelli V, et al. Comparison of rivaroxaban with warfarin for intracardiac thrombosis in the pediatric population at different cardiac sites: Early experience of anticoagulation approach and treatment outcomes. Thromb Res. 2025;253:109397. doi:10.1016/j.thromres.2025.109397
• Gaspari R, Aceto P, Carelli S, et al. Discrepancy Between Conventional Coagulation Tests and Thromboelastography During the Early Postoperative Phase of Liver Resection in Neoplastic Patients: A Prospective Study Using the New-Generation TEG^®6s. J Clin Med. 2025;14(9):2866. doi:10.3390/jcm14092866
• Ibrahim M, Abdullah H, Zafar A, et al. Efficacy and safety of direct oral anticoagulants compared to no anticoagulation for stroke prevention in atrial fibrillation patients with prior intracranial hemorrhage: A systematic review and meta-analysis. Thromb Res. 2025;253:109418. doi:10.1016/j.thromres.2025.109418
• Imai E, Ito H, Okano H, et al. Efficacy and safety of tranexamic acid administration for subarachnoid hemorrhage: a systematic review and meta-analysis. Front Neurol. 2025;16:1617817. doi:10.3389/fneur.2025.1617817
• Logvinsky IK, Sanchez C, Ciuciureanu C, et al. Apixaban- and Rivaroxaban-Associated Bleeding: A Retrospective Analysis Using the FDA Adverse Event Reporting System. Cureus. 2025;17(6):e85509. doi:10.7759/cureus.85509
• Rech MA, Budde E, Evans CT, et al. Andexanet alfa increases 30-day thrombotic events relative to four-factor prothrombin complex concentrate for factor Xa inhibitors-related intracerebral hemorrhage in veterans. Am J Emerg Med. 2025;16:97:97-102. doi:10.1016/j.ajem.2025.07.037
• Thornburg CD, van den Berg HM, Chandler M, et al. Inhibitor development and clinical characteristics in children with severe hemophilia A in the ATHN 8 US cohort study. Blood Vessel Thromb Hemost. 2025;2(3):100082. doi:10.1016/j.bvth.2025.100082
• Wongcharoen W, Pamarapa A, Gunaparn S, et al. Anti-Factor Xa Activity of Apixaban in Extremely Low Body Weight. J Clin Med. 2025;14(15):5238. doi:10.3390/jcm14155238

RESEARCH

• Gandini L, de Veer SJ, Chan CHH, et al. Anticoagulation during Extracorporeal Membrane Oxygenation (ECMO): A Selective Inhibitor of Activated Factor XII Compared to Heparin in an Ex Vivo Model. ACS Pharmacol Transl Sci. 2025;8(5):1260-1269. doi:10.1021/acsptsci.4c00352
• Hellum M, Sletten M, Le MS, et al. Characterization of a novel factor X variant, p.F139L, associated with bleedings in heterozygous and compound heterozygous form. Thromb Res. 2025;253:109412. doi:10.1016/j.thromres.2025.109412
• Jouppila A, Nevola I, Lemponen M, et al. Antiplatelet-anticoagulant, APAC, a mimic of endogenous heparin, is an antithrombotic with von Willebrand factor-mediated characteristics. Thromb Res. 2025;250:109318. doi:10.1016/j.thromres.2025.109318
• Liang J, Nilsson S, Wikström J, et al. Inhibition of Factor XI Using RBD4059: A Novel GalNAc-siRNA With Potent and Durable Antithrombotic Effects. JACC Basic Transl Sci. 2025;10(6):786-797. doi:10.1016/j.jacbts.2024.12.005
• Print EHT, Simmons AM, Spencer HJ, et al. Analyzing 6211 unique variants in the upgraded interactive FVIII web database reveals novel insights into hemophilia A. Blood Vessel Thromb Hemost. 2025;2(3):100053. doi:10.1016/j.bvth.2025.100053
• Rezigue H, Josset L, Nougier C, et al. In vitro effects of Mim8 and combined Mim8-bypassing therapy on thrombin generation, thromboelastography and fibrin clot ultrastructure. Thromb Res. 2025;251:109341. doi:10.1016/j.thromres.2025.109341
• Sang Y, Menegatti M, Brody JA, et al. Plasminogen activation and plasmin activity are not necessary to prevent venous thrombosis/thromboembolism. Blood. 2025;146(11):1346-1358. doi:10.1182/blood.2025028680
• Thomas KA, Liu A, Bark DL Jr, et al. Platelet recruitment kinetics are impacted by von Willebrand factor quality in hemostatic adjuncts. Blood Vessel Thromb Hemost. 2025;2(3):100076.  doi:10.1016/j.bvth.2025.100076
• Treverton J, Arnold DM, Ivanov DG, et al. Monoclonal Antibodies in the Pathogenesis of Heparin-Induced Thrombocytopenia. N Engl J Med. 2025;393(9):879-886. doi:10.1056/NEJMoa2507175
• Wang CY, Wang M, Zhao CY, et al. ADAMTS-13 Prevents VWF-Mediated Gastric Cancer Metastasis. Arterioscler Thromb Vasc Biol. 2025;45(7):e271-e285. doi:10.1161/ATVBAHA.125.322553

METHODS

• Anakmeteeprugsa S, Gonzalez-Fiol A, Garay A, et al. Baseline values for Quantra^® QPlus^® in healthy pregnant women at term and comparison to standard laboratory coagulation values: a prospective observational study. BMC Pregnancy Childbirth. 2025;25(1):826. doi:10.1186/s12884-025-07927-z
• Baker RM, Selby R, Moffat KA, et al. Investigating interassay variability between direct oral anticoagulant calibrated anti-factor Xa assays: a substudy of the perioperative anticoagulation use for surgery evaluation (PAUSE) trial. Res Pract Thromb Haemost. 2025;9(4):102899. doi:10.1016/j.rpth.2025.102899
• Brook R, Suleiman M, Lui B, et al. Global coagulation assays for patients with diabetes and their utility in the prediction of atherothrombotic events. Blood Vessel Thromb Hemost. 2025;2(3):100079.  doi:10.1016/j.bvth.2025.100079
• Denitto S, Salvagno GL, Favaloro EJ, et al. Hemolysis detection accuracy on Stago sthemO 301. Blood Coagul Fibrinolysis. 2025;36(4):134-135. doi:10.1097/MBC.0000000000001359
• Lamoine S, Blanchet JS, Lebreton A, et al. Evaluation of a 4 min 4000 g centrifugation protocol for routine coagulation assays. Blood Coagul Fibrinolysis. 2025;36(5):191-198. doi:10.1097/MBC.0000000000001363
• Laroche P, Feriel J, Chachlica O, et al. An alternative method to assess the long-term stability of frozen plasmas for coagulation testing. Blood Coagul Fibrinolysis. 2025;36(6):300-302. doi:10.1097/MBC.0000000000001374
• Lee JH, Gu JY, Hong J, et al. Concurrence of prothrombin nonneutralizing antibody and factor XI neutralizing inhibitor in lupus anticoagulant positive patient. Blood Coagul Fibrinolysis. 2025;36(4):130-133. doi:10.1097/MBC.0000000000001360
• Monard A, Henskens Y, Heubel-Moenen F. The diagnostic value of the platelet function analyzer in mild to moderate bleeding disorders. J Thromb Haemost. 2025;23(7):2116-2118. doi:10.1016/j.jtha.2025.03.041
• Monard ALL, Hellenbrand D, Verhezen P, et al. tPA-ROTEM identifies hyperfibrinolytic profile in a significant proportion of patients with bleeding disorder of unknown cause (BDUC). Thromb Res. 2025;253:109404. doi:10.1016/j.thromres.2025.109404
• Seetge J, Cséke B, Karádi ZN et al. Viscoelastic Point-of-Care Testing (ClotPro^®) to Guide Intravenous Thrombolysis in Acute Ischemic Stroke Patients on DOACs: Replacing History with Hemostasis in a Proof-of-Concept Study. Neurol Int. 2025;17(7):103. doi:10.3390/neurolint17070103
• Souza MEM, Ferreira LGR, Silva NRO, Lopes LR, das Graças Carvalho M, Rios DRA. Thrombin generation assay in venous thromboembolism: A scoping review. Thromb Res. 2025;252:109384. doi:10.1016/j.thromres.2025.109384